Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28711108 | 0.87 | KMT2A (0.58) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL4245622 | 0.87 | KMT2A (0.58) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL28711109 | 0.86 | KMT2A (0.58) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL2576897 | 0.85 | CYP19A1 (0.48) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL12230963 | 0.85 | KMT2A (0.57) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL4667872 | 0.84 | KMT2A (0.55) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL445196 | 0.84 | ALDH1A1 (0.61) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL2519199 | 0.84 | ALDH1A1 (0.61) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| SCHEMBL537263 | 0.84 | RECQL (0.56) | KMT2ALMNATDP1NAPRTCYP17A1 | |
| Pyridine SCHEMBL28200478 | 0.83 | LMNA (0.58) | KMT2ALMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539062-A | Nicotine carbonate, synthetic method thereof and application thereof in cigarette preparation | 安徽中烟工业有限责任公司 | 2022-05-27 | — | — | CN | claimed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| CN-114539062-A | Nicotine carbonate, synthetic method thereof and application thereof in cigarette preparation | 安徽中烟工业有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114127050-A | Benzopyran and imidazole derivatives useful for stabilizing amyloidogenic immunoglobulin light chains | 斯克利普斯研究所 | 2022-03-01 | — | — | CN | disclosed |
| CN-113226356-A | Activating pyruvate kinase R | 福马治疗股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10364263-B2 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders | Retrophin, Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180362564-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. | 2018-12-20 | — | — | US | disclosed |
| EP-3386995-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Retrophin, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-107383024-B | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| EP-1114052-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017202-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | KMT2A 2637/4885LMNA 4657/4885TDP1 174/4885 |
| US-20180362564-A1 | CYCLIC PHOSPHATES AND CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF NEUROLOGIC DISORDERS | PPA1, PRPS1, PYGB | KMT2A 3665/4885LMNA 1453/4885TDP1 87/4885 |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | KMT2A 4134/4885LMNA 478/4885TDP1 3557/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | KMT2A 3216/4885LMNA 4880/4885TDP1 186/4885 |
| US-10364263-B2 | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders | PPA1, PRPS1, PYGB | KMT2A 3665/4885LMNA 1453/4885TDP1 87/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | KMT2A 4134/4885LMNA 478/4885TDP1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.